[
  {
    "id": 241,
    "question": "Scenario with attached Angio (suggestive of FM-DYSPLASIA) what to do:",
    "option_a": "Renal angio",
    "option_b": "Alpha 1 antitrypsin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nFibromuscular dysplasia (FMD) is a nonatherosclerotic, noninflammatory arteriopathy affecting medium\u2010sized arteries, most classically the renal and carotid arteries. Its angiographic hallmark is the 'string-of-beads' appearance. When an angiogram \u2014 even if originally obtained from a cerebrovascular source \u2014 is suggestive of FMD, it is important to examine other vascular beds that may be involved.\n\n**Pathophysiology**\n\nFMD is believed to result from abnormal cellular proliferation within the arterial wall (most commonly the media), leading to alternating areas of stenosis and aneurysmal dilatation. Although the exact cause remains unclear, hormonal factors (given its predilection for middle\u2010aged women) and genetic factors are thought to contribute. This multifocal vascular involvement means that both cerebral and renal arteries can be affected.\n\n**Clinical Correlation**\n\nClinically, FMD may present with symptoms related to cerebrovascular events (such as transient ischemic attacks or strokes if the carotid arteries are involved) or with renovascular hypertension if the renal arteries are affected. The finding on a cerebral angiogram consistent with FMD should prompt an evaluation for concomitant renal artery involvement, which can have significant implications in blood pressure management.\n\n**Diagnostic Approach**\n\nThe initial diagnosis is usually made by imaging \u2013 typically using duplex ultrasound, CT angiography, MR angiography, or catheter-based digital subtraction angiography. Differential diagnoses include atherosclerotic disease (which tends to produce smooth, concentric stenoses without the beadlike pattern) and vasculitis (which would show inflammatory signs both clinically and on laboratory work-up). Once FMD is suspected in one vascular bed, further evaluation (such as a renal angiogram) is warranted.\n\n**Management Principles**\n\nManagement focuses on controlling blood pressure and mitigating stroke risk. In cases with significant renal artery involvement, percutaneous transluminal angioplasty may be recommended. First-line treatments include risk factor modification and medical management with antihypertensives. In pregnant or lactating women, blood pressure control is crucial and agents such as labetalol or methyldopa (which have better safety profiles in pregnancy) should be considered. Secondary interventional procedures are reserved for severe or refractory cases.\n\n**Option Analysis**\n\nOption A, 'Renal angio,' is appropriate because once FMD is suspected (based on the cerebral angiogram in this scenario), imaging of the renal arteries is indicated to assess possible multisystem involvement. Option B (Alpha 1 antitrypsin) is unrelated, as it pertains to a genetic deficiency primarily linked to lung and liver disease. Options C and D are not provided.\n\n**Clinical Pearls**\n\n1) FMD predominantly affects middle-aged women and is often discovered incidentally or after investigation of a stroke or hypertension. 2) The 'string-of-beads' sign on angiography is pathognomonic. 3) Once FMD is diagnosed in one vascular territory, evaluation for additional involvement (especially of the renal arteries) is essential.\n\n**Current Evidence**\n\nRecent guidelines and consensus statements from vascular and radiologic societies recommend a comprehensive vascular workup in patients with FMD. Advances in non-invasive imaging techniques allow for earlier and more accurate detection, which in turn informs risk factor management and the need for possible revascularization procedures.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 242,
    "question": "Scenario of lateral medullary:",
    "option_a": "PICA",
    "option_b": "no vertebral artery in options",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nLateral medullary syndrome, also known as Wallenberg syndrome, is a classic brainstem stroke syndrome that affects the lateral portion of the medulla oblongata. It is most commonly related to ischemia in the territory of the Posterior Inferior Cerebellar Artery (PICA).\n\n**Pathophysiology**\n\nAn occlusion of the PICA leads to infarction in the lateral medulla. This infarction compromises multiple neural structures including the vestibular nuclei, spinal trigeminal nucleus, nucleus ambiguus, and sympathetic pathways. The resultant deficits reflect the loss of these structures\u2019 functions.\n\n**Clinical Correlation**\n\nPatients typically present with sudden onset of vertigo, nausea, vomiting, dysphagia, hoarseness, ipsilateral facial hypoalgesia (loss of pain and temperature sensation), and contralateral body sensory deficits for pain and temperature. These constellation of symptoms are pathognomonic for lateral medullary syndrome due to PICA occlusion.\n\n**Diagnostic Approach**\n\nDiagnosis is made clinically and confirmed with neuroimaging (CT/MRI) showing infarction in the lateral medulla. Vascular imaging (CTA, MRA, or catheter angiography) can identify the occluded vessel. Differential diagnoses include lateral pontine syndrome (often due to AICA occlusion) and other posterior circulation strokes, which can be differentiated based on both imaging and the specific neurological deficits present.\n\n**Management Principles**\n\nAcute management follows standard stroke care with consideration for intravenous thrombolytic therapy if the patient presents within the appropriate window. Secondary prevention includes the use of antiplatelet agents and management of vascular risk factors. In pregnancy, special care must be taken when considering thrombolysis \u2013 weighing maternal benefits against fetal risks \u2013 and medications with proven safety profiles should be selected.\n\n**Option Analysis**\n\nOption A, 'PICA,' is the correct choice because occlusion of the Posterior Inferior Cerebellar Artery is the most frequent cause of lateral medullary syndrome. Option B mentioning the 'no vertebral artery in options' distracts from the core pathology. Options C and D are not provided.\n\n**Clinical Pearls**\n\n1) Lateral medullary syndrome is characterized by a cross-sensory deficit (ipsilateral facial, contralateral body pain/temperature loss). 2) Occlusion of the PICA is the prototypical cause of this syndrome. 3) Early recognition is crucial for timely intervention, particularly regarding acute stroke management.\n\n**Current Evidence**\n\nCurrent guidelines emphasize rapid neuroimaging and prompt initiation of acute stroke therapies. Recent studies support the use of advanced imaging techniques that enhance early detection of posterior circulation strokes, and further refine selection criteria for thrombolytic or endovascular therapies even in the complex anatomical region of the brainstem.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 243,
    "question": "CSF finding in RCVS:",
    "option_a": "slightly high protein",
    "option_b": "other choices was clearly wrong",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nReversible Cerebral Vasoconstriction Syndrome (RCVS) is characterized by sudden, severe ('thunderclap') headaches and segmental constriction of cerebral arteries that is reversible over time. It typically lacks the inflammatory or infectious changes seen in other CNS vasculopathies.\n\n**Pathophysiology**\n\nRCVS is thought to result from transient disturbances in the regulation of cerebral arterial tone. This leads to multifocal vasoconstriction without the accompanying blood\u2013brain barrier disruption or significant inflammatory response that one would see in infections or primary angiitis of the central nervous system.\n\n**Clinical Correlation**\n\nClinically, patients with RCVS present with recurrent thunderclap headaches. Neurological deficits may arise if the vasoconstriction results in ischemic injury. Since the underlying process is noninflammatory, CSF studies are typically normal or near-normal.\n\n**Diagnostic Approach**\n\nThe workup includes careful neuroimaging (CT, MRI, MRA, or catheter angiography) to document the segmental vasoconstriction and repeat studies to confirm reversibility. A lumbar puncture is performed primarily to exclude subarachnoid hemorrhage or CNS vasculitis. Differential diagnoses include subarachnoid hemorrhage, primary angiitis of the CNS (which usually shows pleocytosis and a more marked protein elevation), and central nervous system infections.\n\n**Management Principles**\n\nFirst-line management generally includes calcium channel blockers (such as nimodipine) to help relieve vasoconstriction and supportive care including pain management. Avoidance of triggers (e.g., vasoactive substances like serotonergic drugs) is also recommended. In pregnant or lactating patients, the use of medications must be carefully considered; agents with more favorable safety profiles (and consultation with maternal\u2013fetal medicine) are preferred.\n\n**Option Analysis**\n\nOption A, 'slightly high protein,' is acceptable in this context. Although RCVS is classically associated with normal CSF, minor nonspecific protein elevation (without significant pleocytosis) can occasionally be observed. The other options (not detailed here) are clearly less representative of the typical CSF findings in RCVS.\n\n**Clinical Pearls**\n\n1) RCVS is best known for its thunderclap headaches and reversible vascular changes on imaging. 2) The CSF in RCVS is typically normal or nearly normal, which helps distinguish it from inflammatory vasculopathies such as primary angiitis of the CNS. 3) Prompt recognition and differentiation from other causes of severe headache are critical to prevent complications.\n\n**Current Evidence**\n\nRecent studies have confirmed that mild CSF protein elevation (if present) in RCVS does not indicate an inflammatory process. Emerging research continues to refine diagnostic criteria and optimal management strategies for RCVS, emphasizing the importance of multimodal imaging and careful clinical monitoring.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 244,
    "question": "Scenario about CADASIL:",
    "option_a": "CADASIL",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nCADASIL stands for Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. It is a hereditary small vessel disease caused by mutations in the NOTCH3 gene, leading to distinctive clinical and radiographic features.\n\n**Pathophysiology**\n\nThe disease is caused by mutations in the NOTCH3 gene, which lead to abnormal accumulation of granular osmiophilic material in the smooth muscle cells of small arteries. This accumulation results in progressive arteriopathy, with consequent subcortical infarcts and white matter changes. The pathophysiological process underpins the clinical signs of migraine, recurrent strokes, and cognitive decline.\n\n**Clinical Correlation**\n\nPatients with CADASIL typically present in early to mid-adulthood with migraine (often with aura), recurrent lacunar strokes, mood disturbances, and a progressive subcortical dementia. MRI findings classically reveal white matter hyperintensities involving the periventricular areas and the anterior temporal lobes.\n\n**Diagnostic Approach**\n\nThe diagnosis of CADASIL is based on a characteristic clinical picture, typical MRI findings, and can be confirmed with genetic testing for NOTCH3 mutations. A skin biopsy demonstrating granular osmiophilic material can also support the diagnosis. Differential diagnoses include other causes of small vessel disease and leukoencephalopathies such as multiple sclerosis or vascular dementia, which can be distinguished based on imaging, family history, and specific clinical features.\n\n**Management Principles**\n\nThere is no curative treatment for CADASIL, so management is primarily supportive. This includes aggressive control of vascular risk factors (such as hypertension and hyperlipidemia), antiplatelet therapy for secondary stroke prevention, and symptomatic management of migraines and mood disturbances. Genetic counseling is crucial for affected individuals and family members. In pregnant or lactating women, special attention to blood pressure control and medication safety is required, with agents selected based on their safety profile in pregnancy (e.g., labetalol for hypertension).\n\n**Option Analysis**\n\nOption A, 'CADASIL,' is the correct answer as it directly names the condition characterized by the clinical and radiological features described in the scenario. The other options, which are not provided in this context, do not align with the classic findings of CADASIL.\n\n**Clinical Pearls**\n\n1) CADASIL should be suspected in patients with a history of migraine with aura, subcortical strokes, and a family history of early-onset dementia or stroke. 2) The anterior temporal pole involvement on MRI is highly suggestive of CADASIL. 3) Genetic confirmation is key for diagnosis and family counseling.\n\n**Current Evidence**\n\nRecent advances emphasize the importance of genetic testing for NOTCH3 mutations in patients with suspected CADASIL. While no disease-modifying treatments exist, ongoing research is focused on potential targeted therapies. Current guidelines stress the importance of risk factor management and genetic counseling to optimize long-term outcomes.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 245,
    "question": "Common question, SCENARIO about progressive symptoms of spinal fistula with attached MRI for spine:",
    "option_a": "DAVF",
    "option_b": "Cavernoma",
    "option_c": "AVM",
    "option_d": "AVF best fits the clinical scenario of progressive symptoms related to a spinal fistula.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nSpinal dural arteriovenous fistula (DAVF) is the most common type of spinal vascular malformation. It involves an abnormal connection between a dural artery and a bridging medullary vein, leading to venous congestion and progressive myelopathy.\n\n**Pathophysiology**\n\nIn DAVF, arterial blood is shunted directly into the venous system without the normal capillary bed. This results in elevated venous pressure, impaired venous drainage, and subsequent spinal cord ischemia. The resulting venous congestion leads to chronic spinal cord edema and neurological deficits.\n\n**Clinical Correlation**\n\nPatients with spinal DAVF typically present with slowly progressive weakness and sensory disturbances in the lower extremities, along with gait abnormalities. The condition is most commonly seen in middle-aged to elderly males. MRI findings often reveal hyperintensity on T2-weighted images in the spinal cord (indicative of edema) and serpiginous flow voids representing dilated vessels.\n\n**Diagnostic Approach**\n\nInitial assessment with MRI of the spine is essential, as it can suggest the diagnosis by showing cord edema and abnormal flow voids. However, spinal angiography remains the gold standard for definitive diagnosis, allowing precise localization and characterization of the fistula. Differential diagnoses include intramedullary arteriovenous malformations (AVMs) and cavernomas, but these have differing clinical and imaging features.\n\n**Management Principles**\n\nThe treatment of spinal DAVF typically involves endovascular embolization or microsurgical disconnection to interrupt the abnormal shunt. In pregnant patients or those who are lactating, careful risk\u2013benefit assessment is necessary as angiographic procedures involve radiation and contrast agents, which may be deferred or managed with modifications based on current guidelines. Multidisciplinary management is crucial to optimize neurological outcomes.\n\n**Option Analysis**\n\nThe options provided were DAVF, cavernoma, and AVM. Cavernomas are usually benign vascular lesions that may present with hemorrhages but do not lead to venous congestion as seen in DAVF. Intramedullary AVMs often present with hemorrhage rather than the progressive myelopathic symptoms typical of DAVF. Thus, the option DAVF best fits the clinical scenario of progressive symptoms related to a spinal fistula.\n\n**Clinical Pearls**\n\nEarly recognition of spinal DAVF is essential as treatment can prevent irreversible spinal cord damage. Clues on MRI such as cord signal hyperintensity and flow voids should lead to angiographic confirmation. A multidisciplinary approach, including neurosurgery and interventional neuroradiology, is recommended.\n\n**Current Evidence**\n\nCurrent guidelines support endovascular embolization as a first-line treatment for spinal DAVF when feasible, with surgical intervention as an alternative in selected cases. Recent studies emphasize the importance of early intervention to halt progression of myelopathy and improve long-term outcomes. Special considerations for pregnant or lactating patients include minimizing fetal radiation exposure and using alternative imaging modalities or protective measures when necessary.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 246,
    "question": "a woman who was being investigated for stroke, was found to have high titer of anti-beta II glycoprotein AB, and anticardiolipin AB. She was diagnosed with antiphospholipid syndrome. she has a history of a prior LL DVT, a small PFO was also found. what is the appropriate management?",
    "option_a": "DAPT",
    "option_b": "warfarin",
    "option_c": "closure of PFO",
    "option_d": "ASA",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAntiphospholipid syndrome (APS) is an autoimmune disorder characterized by the formation of antibodies against phospholipid-binding proteins (notably anticardiolipin and anti-beta2 glycoprotein I). These antibodies predispose patients to both arterial and venous thrombotic events. In this case, the patient\u2019s history, including a prior lower limb DVT and a stroke, is consistent with thrombotic manifestations of APS.\n\n**Pathophysiology**\n\nIn APS, the autoantibodies induce a hypercoagulable state by activating endothelial cells, platelets, and complement pathways, while interfering with the natural anticoagulant mechanisms. This results in an increased risk for clot formation in both the arterial and venous systems. The presence of high titers of anticardiolipin and anti-beta2 glycoprotein I antibodies confirms the autoimmune-mediated coagulation dysregulation.\n\n**Clinical Correlation**\n\nPatients with APS frequently present with recurrent thrombotic events such as DVTs and cerebrovascular accidents (strokes), as seen in this patient. Although a small patent foramen ovale (PFO) was incidentally detected, the hypercoagulable state from APS is the primary concern, and the PFO does not change the management approach in this context.\n\n**Diagnostic Approach**\n\nThe diagnosis of APS is based on the revised Sapporo criteria (or Sydney criteria), which require: 1) a clinical history of vascular thrombosis and/or pregnancy morbidity, and 2) laboratory confirmation of antiphospholipid antibodies (anticardiolipin, anti-beta2 glycoprotein I, or lupus anticoagulant) on two or more occasions at least 12 weeks apart. Differential diagnoses include other hypercoagulable disorders such as inherited thrombophilias, malignancy-related thrombosis, and other autoimmune disorders like systemic lupus erythematosus.\n\n**Management Principles**\n\nLong-term anticoagulation is the cornerstone of management in APS patients with prior thrombotic events. Warfarin is the anticoagulant of choice in nonpregnant patients, with a target INR of 2-3 under standard circumstances. For women who are pregnant or lactating, warfarin is contraindicated due to its teratogenicity, and the recommended management is with low molecular weight heparin (LMWH) combined with low-dose aspirin.\n\n**Option Analysis**\n\nOption A (DAPT) and Option D (ASA) do not provide sufficient anticoagulation in APS. Option C (closure of PFO) is not the primary treatment for preventing thromboembolic events in APS, since the hypercoagulability is the primary driver of thrombotic events rather than embolism through a PFO alone. Therefore, Option B (warfarin) is the best management choice for this patient.\n\n**Clinical Pearls**\n\n1. In APS, always consider long-term anticoagulation as the patient is at high risk for recurrent thrombotic events. 2. Warfarin is the preferred treatment for nonpregnant patients; however, in pregnancy, LMWH with low-dose aspirin is advised. 3. Incidentally found PFOs in the setting of APS do not warrant closure unless they are clearly contributing to embolic events in the absence of a hypercoagulable state.\n\n**Current Evidence**\n\nRecent guidelines and clinical evidence continue to advocate for the use of warfarin in patients with APS and documented thrombotic events to reduce the risk of recurrence. Studies have confirmed that maintaining an INR in the target range (typically 2-3) significantly lowers the risk of further thrombosis. In the event of pregnancy, current recommendations favor LMWH over warfarin due to the known teratogenic effects of the latter.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 247,
    "question": "Scenario about dermatomyositis (they mentioned pt. With weakness and typical skin lesion, and cough) ??? (Not sure about details and choices) Which antibody:",
    "option_a": "Anti synthetase",
    "option_b": "Anti mda5",
    "option_c": "Anti SRP",
    "option_d": "ANTI TIF",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nDermatomyositis is an idiopathic inflammatory myopathy characterized by proximal muscle weakness and distinctive cutaneous findings such as heliotrope rash and Gottron papules. Its subtypes are partly defined by myositis\u2010specific antibodies, each correlating with different clinical patterns and systemic involvements.\n\n**Pathophysiology**\n\nAn autoimmune process leads to muscle fiber injury and a complement-mediated microangiopathy in the skin. Among the antibodies, the anti-synthetase group (most notably anti-Jo1) targets aminoacyl-tRNA synthetases, fostering an inflammatory cascade that can also involve the lungs and result in interstitial lung disease (ILD).\n\n**Clinical Correlation**\n\nIn this scenario, the patient presents with muscle weakness, a classic dermatomyositis skin eruption, and a cough. The presence of cough raises the suspicion for ILD, a well-described feature in patients with anti-synthetase syndrome.\n\n**Diagnostic Approach**\n\nEvaluation involves a combination of clinical examination, serum creatine kinase levels, autoantibody panels (examining myositis-specific antibodies including anti-synthetase), electromyography, and often muscle biopsy. In patients with respiratory symptoms, chest imaging (e.g., high-resolution CT scan) is essential to screen for ILD.\n\n**Management Principles**\n\nThe mainstay of management is high-dose corticosteroids along with additional immunosuppressive agents (such as methotrexate, azathioprine, or mycophenolate mofetil) to control muscle and lung inflammation. In cases with significant ILD, more aggressive immunomodulatory therapy may be warranted. For pregnant and lactating patients, corticosteroids remain the first-line treatment; however, agents such as methotrexate are contraindicated, so alternative therapies with better safety profiles in pregnancy must be chosen.\n\n**Option Analysis**\n\nOption A (Anti-synthetase antibodies) is the best answer in this scenario. Although anti-MDA5 is also associated with ILD, it is more typically seen in clinically amyopathic dermatomyositis with minimal muscle weakness. Anti-SRP is characteristically linked to severe necrotizing myopathy without significant skin manifestations, and anti-TIF1 is more commonly associated with malignancy-related dermatomyositis rather than ILD. The combination of weakness, classic DM rash, and a cough (suggesting ILD) aligns best with an anti-synthetase antibody profile.\n\n**Clinical Pearls**\n\nA cough in a patient with dermatomyositis mandates a thorough evaluation for interstitial lung disease. Identifying the specific autoantibody profile is crucial, as it influences both prognostication and selection of immunosuppressive therapy. Anti-synthetase syndrome, signified by the presence of antibodies such as anti-Jo1, often includes extramuscular manifestations like ILD, arthritis, and mechanic\u2019s hands.\n\n**Current Evidence**\n\nRecent research and guidelines emphasize the importance of myositis-specific antibody testing to tailor immunosuppressive therapy. Early detection and management of ILD significantly improve outcomes, and treatment decisions should carefully incorporate patient factors, including pregnancy and lactation, to ensure safety and efficacy.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 248,
    "question": "Stab wound with ulnar neuropathy what you will find in NCS after 5 days:",
    "option_a": "Decrease recruitment",
    "option_b": "Fibrillations",
    "option_c": "Insertional activity",
    "option_d": "Complex repetitive discharges",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAfter an acute nerve injury such as a stab wound to the ulnar nerve, the muscle fibers begin to show signs of denervation. However, the classical fibrillation potentials that are emblematic of denervation do not typically appear until 10\u201314 days post-injury. Instead, one of the earliest detectable abnormalities on needle electromyography (EMG) is increased insertional activity, which reflects the instability of the muscle membrane when denervated.\n\n**Pathophysiology**\n\nFollowing a nerve injury, Wallerian degeneration ensues distal to the lesion. This process leads to impaired neuromuscular transmission and muscle membrane instability. The increased irritability of these denervated fibers results in abnormal electrical discharges upon insertion of the EMG needle. Fibrillation potentials and positive sharp waves, more specific markers of denervation, take time (typically 10\u201314 days) to develop as the full extent of axonal degeneration becomes evident.\n\n**Clinical Correlation**\n\nIn the setting of a ulnar nerve injury from a stab wound, patients can present with motor deficits (e.g., weakness in ulnar-innervated hand muscles) and sensory disturbances in the ulnar distribution. Early electrodiagnostic studies (around 5 days post-injury) help localize the lesion and estimate the timing of the nerve injury. The presence of increased insertional activity correlates with acute muscle fiber membrane instability secondary to denervation.\n\n**Diagnostic Approach**\n\nThe diagnostic evaluation of acute nerve injuries involves both nerve conduction studies (NCS) and needle EMG. While NCS can demonstrate features such as conduction block and reduced compound muscle action potentials, needle EMG is particularly useful in detecting early spontaneous activity. At 5 days post-injury, the key abnormality is increased insertional activity; fibrillation potentials typically emerge after 7\u201314 days. The differential includes distinguishing between neurapraxia (conduction block without axonal loss) and more severe axonotmesis or neurotmesis.\n\n**Management Principles**\n\nManagement of acute ulnar neuropathy depends on the severity of the injury. Conservative management, including observation and physical therapy, may be appropriate for neurapraxia, while surgical intervention is considered in cases of axonotmesis or neurotmesis. Pregnancy and lactation considerations are critical; when surgical intervention is necessary, one should use anesthetic and surgical medications that are safe in pregnancy and lactation. In addition, non-teratogenic agents should be chosen and multidisciplinary consultation may be warranted to balance maternal and fetal risks.\n\n**Option Analysis**\n\nOption A (Decrease in recruitment) refers to a reduction of motor unit activation on voluntary effort and is less sensitive in the early phase of denervation. Option B (Fibrillations) indeed represents classic signs of denervation but generally are not seen until around 10\u201314 days after the injury, making them less likely at 5 days. Option D (Complex repetitive discharges) are typically associated with chronic changes or reinnervation phenomena. Option C (Insertional activity) is the early abnormal finding on needle EMG attributable to increased muscle fiber irritability shortly after denervation, making it the correct answer.\n\n**Clinical Pearls**\n\nTiming is crucial when interpreting electrodiagnostic studies in nerve injuries. Fibrillation potentials are a late sign (typically emerging after 1\u20132 weeks), whereas increased insertional activity is one of the earliest indicators of denervation. Recognizing the timeline of these findings is essential for accurate diagnosis.\n\n**Current Evidence**\n\nRecent neuromuscular and electrodiagnostic literature confirms that the earliest EMG abnormality in acute nerve injury, such as an ulnar neuropathy secondary to a stab wound, is increased insertional activity. This evidence underscores the importance of performing serial studies if initial exams are inconclusive, particularly in the context of early post-trauma evaluation.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 249,
    "question": "Scenario about essential myoclonus relieved by alcohol asking about dx.",
    "option_a": "Cortical myoclonus",
    "option_b": "Essential myoclonus",
    "option_c": "Physiological myoclonus",
    "option_d": "Epileptic myoclonus",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nEssential myoclonus is an idiopathic movement disorder in which the patient exhibits involuntary, brief, shock\u2010like muscle contractions (myoclonic jerks) in the absence of other neurological abnormalities. Although the term \u2018essential tremor\u2019 is more widely recognized, there is a subset of patients who experience predominantly myoclonic jerks that can be termed as 'essential' if no secondary cause is identified.\n\n**Pathophysiology**\n\nThe underlying mechanism is thought to involve abnormal hyperexcitability in the relevant motor circuits\u2014often at the level of the sensorimotor cortex or subcortical structures\u2014with a disturbance in inhibitory neurotransmission. Unlike epileptic or cortical myoclonus (where discrete electrophysiologic abnormalities and often EEG correlates are noted), essential myoclonus lacks any structural lesion and is presumed to be due to a dysfunction in motor regulation. Although not as well characterized as essential tremor, some patients report improvement with alcohol, which is believed to temporarily modulate GABA\u2010ergic tone.\n\n**Clinical Correlation**\n\nPatients typically present with isolated myoclonic jerks that may be action-induced or present at rest. A notable clinical feature is the improvement of symptoms with the intake of alcohol, which also serves as a supportive clue in the diagnosis. Importantly, these patients do not exhibit other neurological deficits, and their workup (including imaging and routine EEG) is usually unremarkable.\n\n**Diagnostic Approach**\n\nWorkup generally includes a thorough clinical examination, neurophysiological studies such as EMG (which can help differentiate among different types of myoclonus), and sometimes EEG for ruling out epileptic phenomena. Differential diagnoses include cortical or epileptic myoclonus (which are associated with abnormal EEG changes), physiological myoclonus (a normal variant seen in sleep or benign fasciculations), and secondary causes of myoclonus (such as metabolic or toxic states).\n\n**Management Principles**\n\nManagement is largely symptomatic. First-line treatment options include medications such as clonazepam, valproate, or levetiracetam. Since alcohol may transiently improve symptoms, its effect supports the diagnosis but alcohol is not recommended as a treatment strategy. In women who are pregnant or lactating, benzodiazepines and levetiracetam may be used with caution after weighing the risks and benefits, whereas valproate is generally contraindicated due to its teratogenicity.\n\n**Option Analysis**\n\nOption A (Cortical myoclonus) typically implies an epileptic or neurodegenerative process with characteristic EEG findings, which is not the case here. Option C (Physiological myoclonus) represents normal, benign phenomena (e.g., sleep or hiccups) that are transient and do not present as a persistent syndrome. Option D (Epileptic myoclonus) would be accompanied by other seizure-related phenomena and abnormal EEG discharges. Thus, Option B (Essential myoclonus) fits best given the isolated, alcohol-responsive nature of the myoclonic jerks.\n\n**Clinical Pearls**\n\n1. Alcohol responsiveness is a key supportive feature in disorders falling under the 'essential' category (as seen in essential tremor and, less commonly, essential myoclonus). 2. Differentiating between cortical/epileptic myoclonus and essential myoclonus is crucial; the absence of EEG abnormalities and other neurological signs points toward an essential, idiopathic process.\n\n**Current Evidence**\n\nRecent research emphasizes the role of dysfunctional inhibitory neurotransmission in idiopathic movement disorders. While essential tremor is much better characterized in clinical studies, evolving neurophysiological techniques continue to refine our understanding of less common presentations such as essential myoclonus. Guidelines still recommend symptomatic therapy with agents that enhance GABAergic transmission with special consideration for women of childbearing potential.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 250,
    "question": "IV drug user came with acute stroke in 2 hours, CT image attached (good aspect) Was febrile and had a pan systolic murmur. What is the treatment?",
    "option_a": "antibiotics",
    "option_b": "thrombolysis",
    "option_c": "thrombectomy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn patients with acute ischemic stroke, treatment is usually time sensitive. However, in the context of infective endocarditis, which is a well-known source of septic emboli, the management approach differs considerably compared to atherosclerotic strokes.\n\n**Pathophysiology**\n\nInfective endocarditis, particularly in IV drug users, predisposes to the formation of infected vegetations on heart valves. Embolization of these vegetations can lead to ischemic strokes. Unlike typical thromboembolic strokes from atherosclerosis or cardiac mural thrombi, septic emboli carry a risk of causing hemorrhagic conversion and mycotic aneurysms.\n\n**Clinical Correlation**\n\nThe patient\u2019s history of intravenous drug use, the presence of fever, and a pan\u2010systolic murmur strongly point towards infective endocarditis as the underlying etiology of the stroke. In such cases, rapid identification and treatment of the infection are paramount to prevent further embolic events and complications.\n\n**Diagnostic Approach**\n\nThe diagnostic workup in such cases includes blood cultures, echocardiography (transthoracic and/or transesophageal) to identify vegetations on the valves, as well as neuroimaging (CT or MRI) to assess the nature of the stroke. Differential diagnoses include atherosclerotic stroke, cardioembolic stroke from atrial fibrillation, or hemorrhagic stroke. The clinical context and imaging help distinguish septic embolism secondary to endocarditis from these other types.\n\n**Management Principles**\n\nThe primary treatment is the initiation of appropriate intravenous antibiotics tailored to the suspected or identified organism (often covering Staphylococcus aureus in IV drug users). Thrombolysis is contraindicated in infective endocarditis due to the high risk of intracranial hemorrhage and potential worsening of the septic embolic phenomenon. In cases of large vessel occlusion where mechanical thrombectomy is considered, careful evaluation is needed and generally, thrombectomy is not the first-line treatment if an infection is present. In pregnant or lactating patients, antibiotic selection should consider fetal safety, with agents such as penicillins or cephalosporins often preferred.\n\n**Option Analysis**\n\nOption A (antibiotics) is the appropriate treatment given the clinical scenario of presumed infective endocarditis causing septic emboli. Option B (thrombolysis) is contraindicated in the setting of infective endocarditis. Option C (thrombectomy) is not routinely indicated in septic embolic strokes because of the risk of infecting the cerebral vasculature and provoking hemorrhage. Option D is missing and thus not applicable.\n\n**Clinical Pearls**\n\n1. In a febrile patient with IV drug use and a new murmur, always suspect infective endocarditis as a source of embolic stroke. 2. Thrombolysis is contraindicated in infective endocarditis because of the increased risk of hemorrhagic conversion.\n\n**Current Evidence**\n\nRecent guidelines emphasize the need for rapid antibiotic administration in infective endocarditis and caution against the use of thrombolytic therapy in septic embolic strokes due to bleeding risks. Research continues to refine the management strategies in these complex patients, particularly regarding the timing of surgical interventions if indicated.",
    "exam_year": "2020",
    "exam_type": "Part II"
  }
]